GlassScriptPhysician profile
Brittany Busby
NPI 1598434235
$1,095.21
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.37 · 2022: $332 · 2023: $502 · 2024: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $221.34 | 2021-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $173.63 | 2022-2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $162.16 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $142.06 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $93.52 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $81.69 | 2022-2024 | Rexulti |
| Amgen INC. | $45.58 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.45 | 2022-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $44.33 | 2022-2023 | |
| Pfizer INC. | $36.53 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $17.84 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $16.57 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.51 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Busby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.